Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Mezzanine and Stockholders??? Equity (Unaudited)

Condensed Consolidated Statements of Mezzanine and Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Total	Series C Preferred Stock	Series C Preferred Stock Private Placement	Series D Preferred Stock	Series D Preferred Stock Private Placement	Series E Preferred Stock	Series E Preferred Stock Private Placement	AlmataBio Transaction	AlmataBio Transaction Series C Preferred Stock	Common stock	Common stock AlmataBio Transaction	Series C Preferred Stock Series C Preferred Stock	Additional paid-in capital	Additional paid-in capital AlmataBio Transaction	Accumulated deficit
Balance at the beginning (in shares) at Dec. 31, 2023	0
Balance at the beginning at Dec. 31, 2023	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of stock (in shares)			19,946		1		1		2,412
Issuance of Series C Preferred Stock pursuant to AlmataBio Transaction									$ 11,457
Balance at the end (in shares) at Mar. 31, 2024	22,360
Balance at the end at Mar. 31, 2024	$ 11,457
Balance at the beginning (in shares) at Dec. 31, 2023										801,746
Balance at the beginning at Dec. 31, 2023	7,304									$ 1		$ 0	$ 342,437		$ (335,134)
Balance at the beginning (in shares) at Dec. 31, 2023												0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Impact of reverse split fractional share round-up (in shares)										60,779
Issuance of common stock pursuant to Almata Transaction (in shares)											171,605
Issuance of common stock pursuant to AlmataBio Transaction								$ 815						$ 815
Stock-based compensation	629												629
Net loss	(121,290)														(121,290)
Balance at the end (in shares) at Mar. 31, 2024										1,034,130
Balance at the end at Mar. 31, 2024	$ (112,542)									$ 1		$ 0	343,881		(456,424)
Balance at the end (in shares) at Mar. 31, 2024												0
Balance at the beginning (in shares) at Dec. 31, 2024	2			1		1
Balance at the beginning at Dec. 31, 2024	$ 0			$ 0		$ 0
Balance at the end (in shares) at Mar. 31, 2025	2			1		1
Balance at the end at Mar. 31, 2025	$ 0			$ 0		$ 0
Balance at the beginning (in shares) at Dec. 31, 2024	10,471,934									10,471,934
Balance at the beginning at Dec. 31, 2024	$ 133,032									$ 10		$ 0	503,285		(370,263)
Balance at the beginning (in shares) at Dec. 31, 2024		24,896										24,896
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in exchange for retirement of Series C Preferred Stock (in shares)										200,000
Issuance of common stock in exchange for retirement of Series C Preferred Stock	1									$ 1
Issuance of common stock in exchange for retirement of Series C Preferred Stock (in shares)		(200)										(200)
Vesting of Restricted Stock Units net of shares withheld for taxes (in shares)										155,686
Vesting of Restricted Stock Units net of shares withheld for taxes	(510)												(510)
Stock-based compensation	3,241												3,241
Net loss	$ (13,149)														(13,149)
Balance at the end (in shares) at Mar. 31, 2025	10,827,620									10,827,620
Balance at the end at Mar. 31, 2025	$ 122,615									$ 11		$ 0	$ 506,016		$ (383,412)
Balance at the end (in shares) at Mar. 31, 2025		24,696										24,696